PathAI, a Boston, MA-based provider of artificial intelligence-powered technology for use in pathology research, secured an investment from LabCorp (NYSE: LH), a global life sciences company.
The amount of the deal was not disclosed.
The company intends to use the funds to expand clinical development of artificial intelligence-enabled computational pathology and advance its eventual integration with clinical laboratories.
Led by co-founder and Chief Executive Officer Andy Beck M.D., Ph.D., PathAI is a provider of AI-powered research tools and services for pathology. Its platform aims to improve the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
The company works with leading life sciences companies and researchers to advance precision medicine.
LabCorp’s investment follows a $60m round of funding into PathAI announced last month, led by global growth equity firm General Atlantic and venture capital firm General Catalyst.